Vancomycin creep and Daptomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus.

Objective: To determine the in vitro activity of daptomycin and vancomycin against 50 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated from blood and pus specimens. Material and methods: Fifty consecutive MRSA were isolated from pus (n=25) and blood (n=25) were included in the study. Oxacillin susceptibility was determined by cefoxitin disc diffusion, green colored colonies on chromogenic media. Susceptibility testing for 18 antimicrobial agents was determined by a disc diffusion method. The minimum inhibitory concentration (MIC) of daptomycin and vancomycin was determined by the Etest as recommended by the Clinical and Laboratory Standards Institute (CLSI). Results: Antibiotic susceptibility pattern of the MRSA isolates showed that 38% were multi-drug resistant overall and 52% in blood and 24% in pus isolates when expressed separately. The MIC50 and MIC90 of daptomycin were 0.08 and 0.09 mg/L and of vancomycin were 1.2 mg/L and 1.3 mg/L, respectively. Ten percent of the isolates had vancomycin MIC of 2 mg/L which is the upper limit of CLSI breakpoint for sensitive isolates. None of the isolates showed intermediate susceptibility or resistance to vancomycin or daptomycin. Conclusion: Creeping MIC of vancomycin is a matter of concern and MIC of 1.5–2 mg/L of vancomycin in MRSA increases the risk of development of complicated bacteraemia. MIC’s of vancomycin should be reported for all S. aureus isolates and should be used to guide treatment. Otherwise, daptomycin can be considered as an alternative antibiotic for therapy of MRSA infections in India. Key words: Vancomycin , Daptomycin, Methicillin-resistant Staphylococcus aureus (MRSA) , Minimum Inhibitory Concentration (MIC),

[1]  C. Shivannavar,et al.  Vancomycin resistance among methicillin resistant Staphylococcus aureus isolates from intensive care units of tertiary care hospitals in Hyderabad , 2011, The Indian journal of medical research.

[2]  Joshua A. Doherty,et al.  Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. , 2006, Chest.

[3]  S. Kaplan.  Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. , 2005, The Pediatric infectious disease journal.

[4]  Benjamin A Lipsky,et al.  Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. , 2005, The Journal of antimicrobial chemotherapy.

[5]  R. Arbeit,et al.  The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Jerome J. Schentag,et al.  Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Ward,et al.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Arjun Srinivasan,et al.  Vancomycin Resistance in Staphylococci , 2002, Clinical Microbiology Reviews.

[9]  J. Alder,et al.  Daptomycin: a novel lipopeptide antibiotic , 2002 .

[10]  A. Barry,et al.  Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. , 2001, The Journal of antimicrobial chemotherapy.

[11]  F. Tenover,et al.  Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. , 2001, Emerging infectious diseases.

[12]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[13]  E. Concia,et al.  Penetration of vancomycin into human lung tissue. , 1996, The Journal of antimicrobial chemotherapy.

[14]  A. Kumar,et al.  Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus , 2008 .

[15]  T. Fatma,et al.  Detection of vancomycin resistant Staphylococcus aureus: a comparative study of three different phenotypic screening methods. , 2005, Indian journal of medical microbiology.

[16]  F. Daschner,et al.  Penetration into tissues of various drugs active against gram-positive bacteria. , 1991, Journal of Antimicrobial Chemotherapy.